BioCentury
ARTICLE | Company News

Fougera, Novartis deal

May 7, 2012 7:00 AM UTC

Novartis' Sandoz Ltd. generics unit will acquire dermatology generics company Fougera for $1.5 billion in cash. Fougera (formerly Nycomed US Inc.) was the U.S. dermatology subsidiary of Nycomed before it became a standalone company following Nycomed's acquisition last year by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Tokyo, Japan) for €9.6 billion ($13.8 billion). Fougera's sellers are a group of private equity firms led by Nordic Capital Funds; DLJ Merchant Banking Partners; and Avista Capital Partners (see BioCentury, Oct. 3, 2011). ...